SUMMARY a-and b-neurexins are presynaptic cell-adhesion molecules implicated in autism and schizophrenia. We find that, although b-neurexins are expressed at much lower levels than a-neurexins, conditional knockout of b-neurexins with continued expression of a-neurexins dramatically decreased neurotransmitter release at excitatory synapses in cultured cortical neurons. The b-neurexin knockout phenotype was attenuated by CB1-receptor inhibition, which blocks presynaptic endocannabinoid signaling, or by 2-arachidonoylglycerol synthesis inhibition, which impairs postsynaptic endocannabinoid release. In synapses formed by CA1-region pyramidal neurons onto burst-firing subiculum neurons, presynaptic in vivo knockout of b-neurexins aggravated endocannabinoid-mediated inhibition of synaptic transmission and blocked LTP; presynaptic CB1-receptor antagonists or postsynaptic 2-arachidonoylglycerol synthesis inhibition again reversed this block. Moreover, conditional knockout of b-neurexins in CA1-region neurons impaired contextual fear memories. Thus, our data suggest that presynaptic b-neurexins control synaptic strength in excitatory synapses by regulating postsynaptic 2-arachidonoylglycerol synthesis, revealing an unexpected role for b-neurexins in the endocannabinoid-dependent regulation of neural circuits.
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In Brief b-neurexins have a surprisingly distinct and selective role in regulating neurotransmitter release in the hippocampus and in maintaining conceptual fear memories. They act to trans-synaptically downregulate tonic endocannabinoid signaling, whose presence at excitatory hippocampal neurons was unexpected.
INTRODUCTION
Synaptic cell-adhesion molecules play critical roles in establishing and restructuring synaptic connections throughout life. Neurexins are evolutionarily conserved presynaptic cell-adhesion molecules that engage in trans-synaptic interactions with multifarious postsynaptic ligands, including neuroligins (NLs), cerebellins, and LRRTMs (Krueger et al., 2012; Sü dhof, 2008) . In mammals, neurexins are encoded by three genes, each of which contains independent promoters for longer a-and shorter b-neurexins (Rowen et al., 2002; Tabuchi and Sü dhof, 2002; Ullrich et al., 1995; Ushkaryov et al., 1992 Ushkaryov et al., , 1994 . b-neurexins are N-terminally truncated versions of a-neurexins that contain only a short ($40 residues) b-specific N-terminal sequence that then splices into the middle of the a-neurexin sequences (Ushkaryov et al., 1992) . a-and shorter b-neurexin transcripts are extensively alternatively spliced at six canonical sites, resulting in over 1,000 distinct neurexin mRNAs Treutlein et al., 2014) .
Although neurexins are well studied, little is known about their fundamental functions. Ligands that bind to either both a-and b-neurexins (e.g., neuroligins, LRRTMs, dystroglycan, and cerebellins; Ichtchenko et al., 1995 , Ko et al., 2009 de Wit et al., 2009; Siddiqui et al., 2010 , Uemura et al., 2010 or only to a-neurexins (e.g., neurexophilins; Petrenko et al., 1996) have been described, and constitutive knockouts (KOs) of a-neurexins were shown to severely impair neurotransmitter release (Missler et al., 2003) . However, only a limited understanding of a-neurexin functions is available, and little is known about b-neurexins. The lack of information on b-neurexin functions is particularly striking because nearly all biochemical studies on neurexins were performed with b-neurexins. Elucidating the synaptic actions of neurexins is a major technical challenge given their diversity and complexity. This challenge has taken on added importance given that hundreds of neurexin mutations were associated with several neuropsychiatric disorders (Sü dhof, 2008; Bang and Owczarek, 2013; Clarke and Eapen, 2014) .
To specifically assess the function of b-neurexins, we generated mutant mice carrying conditional KO (cKO) alleles of all three b-neurexins. Despite a low abundance of b-neurexin transcripts, we found that KO of b-neurexins in cultured neurons in vitro and in hippocampus in vivo impaired neurotransmitter release at excitatory synapses. Surprisingly, this decrease was due, at least in part, to enhanced tonic activation of presynaptic CB1-receptors (CB1Rs), caused by increased postsynaptic synthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG). Moreover, synapses of hippocampal CA1 pyramidal cells onto pyramidal neurons in the subiculum-the major output pathway of the hippocampus-were differentially regulated by endocannabinoids, and deletion of b-neurexins selectively impaired the function of the more strongly endocannabinoidregulated synapses in the subiculum. The importance of this circuit-specific synaptic alteration emerged from behavioral studies, showing that the b-neurexin KO in the adult CA1 region produced an impairment of contextual fear memory. Thus, b-neurexins are produced as minor transcripts of neurexin genes that nevertheless are essential for the regulation of mammalian synaptic circuits due to modulation of endocannabinoid signaling via an unanticipated trans-synaptic mechanism.
RESULTS

Generation of b-Neurexin-Specific Conditional Triple-KO Mice
Using qRT-PCR, we found that throughout the brain, all three b-neurexins were expressed at levels 10-to 100-fold lower than are corresponding a-neurexins ( Figures 1A and S1 ). Despite their low abundance, however, b-neurexins are highly conserved and might still perform essential functions. To test this hypothesis, we generated conditional and constitutive KO mice of all b-neurexin genes . In these mice, the 5 0 exon that encodes the N-terminal b-neurexin-specific sequences was flanked by loxP sites, and epitope tags were inserted into the b-neurexin-specific sequences (EGFP for neurexin-1b and -3b; a hemagglutinin [HA] tag for neurexin-2b). We generated single-, double-, and triple-conditional and constitutive b-neurexin KO mice (see the Experimental Procedures for details) and focused our analyses on triple-mutant mice, targeting all b-neurexins to brace for potential redundancies among b-neurexins.
Conditional triple KO (cKO) mice were viable and fertile. The EGFP and HA tags did not alter expression of either a-or b-neurexin mRNAs ( Figures S2D and S2E ). Probably because of their low expression levels, tagged b-neurexins could not be detected in total brain extracts, but were readily observed after immunoprecipitations of b-neurexins with EGFP antibodies ( Figure 1C ).
Constitutive triple-b-neurexin KO mice were also viable but were significantly smaller than wild-type mice and unable to reproduce ( Figure S2F ). Even single-neurexin-2b and -3b KO mice exhibited a significantly reduced body weight. Thus, b-neurexins-despite low abundance and in contrast to a-neurexins (Missler et al., 2003) -are important for animal health but are not essential for animal survival.
Conditional b-Neurexin KO Impairs Neurotransmitter Release at Excitatory Synapses We cultured cortical neurons from triple-b-neurexin cKO mice and infected them with lentiviruses expressing active (Cre; to delete all b-neurexins) or inactive, truncated Cre-recombinase (DCre; as a control). b-neurexin KO neurons exhibited no change in dendritic arborization or synaptic morphology, suggesting normal neuronal development ( Figures 1D, 1E , S3, and S4A-S4E). We evoked action potential-induced excitatory and inhibitory postsynaptic currents (EPSCs and IPSCs, respectively; Kaeser et al., 2011) and separately monitored pharmacologically isolated AMPA-receptor (AMPAR)-and NMDA-receptor (NMDAR)-mediated EPSCs and GABA-receptor (GABAR)-mediated IPSCs. Strikingly, the b-neurexin KO decreased both AMPAR-and NMDAR-mediated EPSCs by $50%, but had no effect on GABAR-mediated IPSCs ( Figures 1F-1H) .
These results suggest that the b-neurexin KO caused a decrease in the probability of glutamate release at excitatory synapses. To directly test this hypothesis, we measured presynaptic release probability using the progressive use-dependent block of evoked NMDAR EPSCs by MK-801 (Hessler et al., 1993; Rosenmund et al., 1993) . We observed in triple-b-neurexin KO neurons a robust, $2-fold decrease in the rate of synaptic NMDAR inactivation in the presence of MK-801, suggesting an $2-fold decrease in release probability ( Figure 1I ). This decrease was not due to a change in the readily releasable pool of synaptic vesicles because the b-neurexin deletion had no effect on hypertonic sucrose-evoked EPSCs ( Figure 1J ). Figure 2A ). After lentiviral expression in neurons, GCaMP5G-Syb2 was efficiently targeted to presynaptic terminals ( Figure 2B ). To restrict analyses of presynaptic Ca 2+ transients to excitatory synapses, we sparsely transfected neurons with mCherry and monitored action potential-elicited Ca 2+ transients only in presynaptic boutons contacting postsynaptic dendritic spines ( Figure 2B ). Figure 2C ). We found that KO of b-neurexins significantly attenuated action potential-induced Ca 2+ -transients, with an overall $2-fold decrease ( Figures 2D and 2E) . KO of b-neurexins had no effect on presynaptic levels of voltage-gated N-or P/Qtype Ca 2+ -channels, suggesting a functional impairment .
Viewed together, these data show that the b-neurexin KO causes a $2-fold decrease in three excitatory synapse parameters: EPSC amplitude, release probability, and action-potentialinduced Ca 2+ influx. This suggests that b-neurexins, despite their low abundance compared to a-neurexins, are selectively essential for normal action-potential gated Ca 2+ influx during neurotransmitter release at excitatory synapses. (Xu et al., 2009 ). The b-neurexin KO substantially depressed the mEPSC frequency ($2-fold), slightly decreased the mEPSC amplitude, and lowered the surface levels of GluA1 AMPARs ( Figures 3A, 3B , S4I, and S4J). However, b-neurexin KO had no effect on mIPSC frequency and amplitude (Figures 3C and 3D) , consistent with the selective suppression of the presynaptic release probability by the b-neurexin KO in excitatory, but not in inhibitory, synapses.
To validate the specificity of the b-neurexin KO effects on neurotransmitter release, we used ''mini'' release as a measure of release probability and tested the ability of neurexin-1b containing or lacking an insert in splice site #4 (SS4) and of neurexin-1a lacking an insert in SS4 to rescue the phenotype. Only neurexin-1b lacking an insert in SS4 rescued the decrease in excitatory synaptic transmission in b-neurexin KO neurons ( Figures 3E and 3F ). Neurexin-1b lacking an insert in SS4 also enhanced mEPSC amplitude, probably because this neurexin splice variant stabilizes postsynaptic AMPARs (Aoto et al., 2013) . The SS4-dependent rescue of the triple-b-neurexin KO phenotype not only validates its overall specificity but also suggests that b-neurexins control synaptic strength via a specific interaction with postsynaptic ligands that do not bind to a-neurexins. Alternative splicing at SS4 dramatically influences neurexin binding to postsynaptic ligands (Boucard et al., 2005; Chih et al., 2006; Ko et al., 2009; Siddiqui et al., 2010; Uemura et al., 2010; Matsuda and Yuzaki, 2011) . Indeed, we observed that at least some neuroligin-1 splice variants specifically bind only to b-neurexins, but not to a-neurexins lacking an insert in SS4 ( Figure S5I ).
b-Neurexin KO Enhances Basal Endocannabinoid Activity
How might deletion of b-neurexins influence presynaptic Ca 2+ influx? A hint derives from the synaptic dysfunction caused by the neuroligin-3 KO, a postsynaptic cell-adhesion molecule that binds to presynaptic neurexins (Sü dhof, 2008) . In CA1 pyramidal neurons, the neuroligin-3 KO decreases tonic endocannabinoid signaling, mediated by cannabinoid receptor type 1 (CB1R), at inhibitory synapses from CCK-positive basket neurons, thereby increasing GABA release (Fö ldy et al., 2013) . This observation led us to ask whether the b-neurexin KO might cause the opposite change at excitatory synapses, i.e., an increase in basal endocannabinoid signaling, that could account for the decrease in Ca 2+ influx and neurotransmitter release in b-neurexin KO synapses.
We tested the effect of the CB1R antagonist AM251 on mEPSCs, again used as a measure of presynaptic release probability. AM251 had no effect on the mEPSC amplitude or frequency in control neurons . However, AM251 significantly enhanced the mEPSC frequency without changing the mEPSC amplitude in b-neurexin KO neurons , suggesting that KO of b-neurexins enhances basal endocannabinoid tone.
To further explore this hypothesis, we examined the effects of the CB1R agonist WIN (WIN55,212-2 mesylate) on mEPSCs. While WIN produced a similar relative decrease in mEPSC frequency in triple-b-neurexin KO and control neurons ( Figure S5G ), we observed a significantly smaller absolute decrease in mEPSC frequency in KO neurons (Figures 3H and S5H) . This observation, consistent with the findings from the AM251 experiments, suggests that in b-neurexin KO synapses, CB1Rs are partially activated, and thus less additional inhibition is induced by WIN. Together, these data indicate that the b-neurexin KO caused an Figure S4 .
increase in the basal activity of presynaptic CB1Rs, which are known to inhibit presynaptic Ca 2+ channels and to decrease neurotransmitter release (Twitchell et al., 1997; Kreitzer and Regehr, 2001; Brown et al., 2004; Szabó et al., 2014) . Consistent with observations on neuroligin-3 (Fö ldy et al., 2013), these data reveal a connection of the neurexin/neuroligin complex to endocannabinoid signaling. The direction of the effects, however, is diametrically opposite: whereas the b-neurexin KO suppresses the presynaptic neurotransmitter release probability at excitatory synapses, the neuroligin-3 KO increases release at inhibitory synapses.
Conditional b-Neurexin KO Increases Postsynaptic 2-AG Synthesis To begin to explore how the b-neurexin KO increases the basal endocannabinoid ''tone'' at excitatory synapses, we examined CB1R levels in b-neurexin KO neurons by immunoblotting and immunocytochemistry. We detected no changes, suggesting that presynaptic b-neurexins may influence endocannabinoid synthesis, which is postsynaptic (Figures 4A-4D ; Murataeva et al., 2014 , Castillo et al., 2012 , Di Marzo et al., 2004 . To test which of the brain's two major endocannabinoids-2-AG and anandamide-is active at the synapses that are affected by the b-neurexin KO, we measured the effects of exogenous 2-AG and anandamide on mEPSCs in control and b-neurexin KO neurons. Bath-applied anandamide had only a modest effect on mEPSCs in cultured cortical neurons, with no significant difference between control and b-neurexin KO neurons. In contrast, 2-AG robustly suppressed mEPSC frequency in control neurons, but not in b-neurexin KO neurons ( Figures 4E and 4F ). This observation, consistent with the findings from the AM251 and WIN experiments ( Figures 3G and 3H) , suggests that the b-neurexin KO partially activates CB1Rs by increasing basal levels of 2-AG, which prevents the additional inhibition by exogenous 2-AG. Anandamide is likely relatively inactive because it is a partial agonist and may not primarily act via CB1Rs (Freund et al., 2003) .
2-AG is synthesized via a postsynaptic phospholipase C-dependent pathway ( Figure 4A ). To test whether postsynaptic 2-AG synthesis may be upregulated upon loss of presynaptic b-neurexins, we blocked phospholipase C-dependent 2-AG synthesis specifically in postsynaptic neurons by introducing the phospholipase C inhibitor U73122 via the patch pipette into postsynaptic neurons. U73122 had only minimal effects in control neurons, but caused full rescue of the mEPSC frequency in b-neurexin KO neurons ( Figure 4G ).
Together, these data suggest that increased postsynaptic 2-AG synthesis produces the presynaptic b-neurexin KO phenotype. To (legend continued on next page) consolidate this conclusion, we assayed the state of CB1Rs as a function of postsynaptic 2-AG synthesis inhibition. We bathapplied the CB1R-antagonist AM251 ( Figure 4H ) or the CB1R-agonist 2-AG ( Figure 4I ), while recording from postsynaptic neurons containing the 2-AG synthesis inhibitor U73122. U73122 eliminated the enhanced basal activity of CB1Rs in b-neurexin KO neurons ( Figures 3G and 4H ) and restored the sensitivity of CB1Rs to exogenous 2-AG ( Figures 4F and 4I) . Thus, postsynaptic inhibition of 2-AG synthesis in b-neurexin KO neurons restores the signaling set-point of presynaptic CB1Rs to that observed in control neurons, confirming that b-neurexins activate presynaptic CB1Rs via an upregulation of postsynaptic 2-AG synthesis.
Conditional b-Neurexin KO In Vivo Suppresses Release at Hippocampal Output Synapses Modulation of endocannabinoid signaling by b-neurexins would have significant circuit implications and could be relevant not only for understanding abnormalities of circuit dynamics in neuropsychiatric disorders but also for possible future therapeutic options. Thus, we tested whether b-neurexins also control endocannabinoid signaling in vivo.
We stereotactically injected AAVs encoding Cre-EGFP or DCre-EGFP into the hippocampal CA1 region of triple-b-neurexin cKO mice at P21 and analyzed acute subiculum slices at P35-P40 ( Figure 5A ). We monitored synaptic transmission at synapses formed by CA1-region axons onto pyramidal neurons of the subiculum, which is the major output pathway of the hippocampus. In this approach, only presynaptic neurons are genetically manipulated (Aoto et al., 2013) . Pyramidal subiculum neurons comprise two broad classes-''regular-firing'' and ''burst-firing'' neurons-that can be readily distinguished by the pattern of action potentials induced by current injections ( Figure 5B ; Graves et al., 2012; Staff et al., 2000; van Welie et al., 2006) . All analyses were performed separately in these two classes of neurons. Upon whole-cell break-in, we identified the neuron type in current-clamp mode and then recorded EPSCs induced by stimulating CA1-region axons in voltageclamp mode ( Figure 5B ).
We assessed excitatory synaptic strength by measuring the input-output relationship ( Figures 5C and 5D ). In regular-firing neurons, the b-neurexin KO produced a trend toward decreased synaptic strength ( Figure 5C ). In burst-firing neurons, however, the b-neurexin KO caused a $2-fold decrease in synaptic strength, similar to cultured cortical neurons ( Figure 5D ). Moreover, we measured paired-pulse ratios (PPRs) that inversely correlate with the presynaptic release probability (Kaeser and Regehr, 2014) . Again, the presynaptic b-neurexin KO caused no change in regular-firing neurons ( Figure 5E ), but increased the PPR in burst-firing neurons, consistent with a decrease in release probability ( Figure 5F ). Thus, the presynaptic b-neurexin KO selectively decreases neurotransmitter release in burst-firing neuron synapses.
b-Neurexins Control Endocannabinoid Regulation of Subiculum Synapses
Does the presynaptic b-neurexin KO impair neurotransmitter release in burst-firing subiculum neuron synapses by an endocannabinoid-dependent mechanism similar to cultured cortical neurons? To address this question, we first needed to learn whether tonic endocannabinoid signaling normally regulates release at subiculum synapses. Bath application of the CB1R antagonist AM251 had no effect on EPSC amplitudes in regular-firing neurons, but caused a significant enhancement of EPSCs in burst-firing neurons ( Figure 5G ). Bath application of the CB1R agonist WIN, conversely, induced a modest depression of EPSCs in regular-firing neurons but a significantly stronger depression of EPSCs in burst-firing neurons ( Figure S6A ). Thus, endocannabinoids tonically modulate excitatory synapses formed onto burst-firing neurons and perform a smaller role at synapses formed onto regular-firing neurons.
Next, we explored whether the b-neurexin KO decreases neurotransmitter release in burst-firing neuron synapses by increasing basal endocannabinoid tone. To this end, we bathapplied AM251 to subiculum slices without or with presynaptic KO of b-neurexins. Presynaptic b-neurexin KO caused a significant increase in the AM251-dependent enhancement of EPSCs ( Figure 5H ), suggesting that similar to cultured neurons in vitro ( Figure 3G ), the b-neurexin KO increased endocannabinoiddependent inhibition of release in burst-firing neuron synapses in vivo ( Figure 5H ). The b-neurexin KO did not change the relative magnitude of the EPSC depression by WIN ( Figures S5G and  S6B) , likely because the enhanced basal CB1R activity is not saturated by loss of b-neurexins. Together, these findings suggest that the b-neurexin KO decreases excitatory synaptic strength in burst-firing subiculum neurons, at least in part, by enhancing tonic activation of CB1Rs in presynaptic terminals of CA1 pyramidal neurons. Data are means ± SEM; the numbers of neurons/ mice examined are shown in the summary graphs. Statistical analysis was by paired Student's t test for single-cell plots and unpaired Student's t test for comparisons in other summary graphs (*p < 0.05; **p < 0.01; ***p < 0.001). See also Figure S6 .
b-Neurexins Control Long-Term Plasticity in BurstFiring Neuron Synapses
In regular-firing neurons of the subiculum, LTP is induced by postsynaptic activation of NMDARs, whereas in burst-firing neurons LTP is induced by presynaptic activation of PKA (Wozny et al., 2008; Behr et al., 2009) . We asked whether LTP may also be differentially affected by the presynaptic b-neurexin KO in regular-and burst-firing neurons, similar to endocannabinoid signaling. We observed no effect of the b-neurexin KO on LTP in regular-firing neurons ( Figure 6A ). Strikingly, however, the b-neurexin KO blocked LTP in burst-firing neurons ( Figure 6B ). Presynaptic LTP in burst-firing neurons depends on adenylate cyclase/PKA signaling (Wozny et al., 2008) . Interestingly, CB1Rs are coupled to Ga i , which inhibits adenylate cyclase (Castillo et al., 2012; Kano et al., 2009 ). Thus, we hypothesized that enhanced basal CB1R activity caused by the b-neurexin KO may contribute to, or even cause, the LTP impairment. To test this hypothesis, we examined the effects of AM251 on LTP in burst-firing subiculum neurons. AM251 had no effect on LTP in control neurons ( Figure 6C ), but rescued the blocked LTP in b-neurexin KO neurons ( Figure 6D ). To examine whether the mechanism of CB1R activation by the b-neurexin KO in LTP mirrors that of CB1R activation in release, we asked whether postsynaptic inhibition of 2-AG synthesis also rescued the LTP impairment in b-neurexin KO synapses. Indeed, selective introduction of the 2-AG synthesis inhibitor U73122 into postsynaptic patched neurons ( Figure 4A ) had no effect on LTP in control slices but fully rescued the block of LTP in b-neurexin KO slices ( Figures 6E and 6F) . These results suggest that following the genetic ablation of b-neurexins, tonic postsynaptic 2-AG synthesis is enhanced and activates presynaptic CB1Rs, which impair this form of LTP.
Deletion of b-Neurexins in CA1 Region Neurons Impairs Contextual Fear Memory
To examine whether the function of b-neurexins in hippocampal CA1 neurons is important for learning and memory, we tested the behavioral effects of deleting b-neurexins from the hippocampal CA1 region (Figures 7A and 7B) . We observed no changes in the open-field behavior of mice, as measured quantitatively on a force actometer ( Figures 7C and S7A) . We then performed simultaneous cued and contextual fear conditioning. The CA1-region-specific b-neurexin KO did not impair fear-learning acquisition ( Figure S7B ), but strongly reduced freezing behavior when the mouse was placed in the context of the tone-foot-shock pairings ( Figure 7D ). This phenotype was specific for contextual memory since the b-neurexin KO had no effect on freezing in response to an altered context or to the auditory cue, indicating that contextual fear memory-which is known to be dependent on hippocampal function (Fanselow and Dong, 2010) -is selectively impaired by the b-neurexin KO ( Figure 7D ).
DISCUSSION
We analyzed triple-conditional KO mice that target all b-neurexin genes in two preparations: cultured cortical neurons after conditional KO of b-neurexins in vitro, and acute subiculum slices after conditional presynaptic KO of b-neurexins in vivo. Our data demonstrate that b-neurexins regulate the strength and longterm plasticity of a subset of excitatory synapses, that the b-neurexin KO impairs presynaptic Ca 2+ influx triggered by an action potential in these synapses, and that presynaptic b-neurexins control tonic postsynaptic endocannabinoid signaling mediated by 2-AG ( Figure 7D ). Our in vivo results further suggest that b-neurexins regulate neural circuits by modulating the strength and plasticity of a subset of excitatory synapses via endocannabinoids and that this regulation is behaviorally important. Given the complex nature of the many overlapping neural circuits that ultimately guide behavior, it is perhaps not surprising that the endocannabinoid-dependent modulation of synaptic circuits is controlled by trans-synaptic cell-adhesion molecules, and that this control is essential for the information processing capacity of the brain. However, it is unexpected that b-neurexins as relatively minor neurexin gene transcripts perform a pervasive regulatory role in synapses, a role that adds to previously defined other functions of neurexins (Missler et al., 2003; Aoto et al., 2013 Aoto et al., , 2015 . In cultured cortical neurons in vitro, KO of b-neurexins decreased the release probability at excitatory synapses $2-fold by causing a $2-fold decrease in presynaptic Ca 2+ transients ( Figures 1F-1J, 2D , 2E, and 3A-3D). The magnitude of this effect was surprising considering the low expression of b-neurexins ( Figure 1A ) and the continued presence of the more abundant a-neurexins. The underlying mechanism consisted, at least in part, of an increase in tonic 2-AG endocannabinoid signaling, as evidenced by the reversal of the release phenotype, both by bath-application of the CB1R-antagonist AM251 ( Figure 3G ) and by postsynaptic inhibition of 2-AG synthesis ( Figure 4G ). Thus, b-neurexins appear to be selectively essential for regulating excitatory synaptic strength via a control of tonic endocannabinoid signaling.
In synapses formed by CA1-region pyramidal neurons onto pyramidal neurons in the subiculum in vivo, the b-neurexin KO also impaired excitatory synaptic transmission. We separately examined synapses of regular-and burst-firing neurons, the two types of subiculum pyramidal neurons (Staff et al., 2000; van Welie et al., 2006) . The presynaptic b-neurexin KO produced a decrease of excitatory synaptic strength in postsynaptic burstfiring, but not regular-firing, neurons; this loss was reversed, at least in part, by the CB1R antagonist AM251 (Figure 5 ). Moreover, only PKA-dependent presynaptic LTP in burst-firing, but not NMDAR-dependent postsynaptic LTP in regular-firing, neurons was impaired by the b-neurexin KO (Figures 6A and 6B ). Presynaptic LTP in presynaptic b-neurexin KO slices was restored by inhibiting CB1Rs (Figures 6C and 6D) and, most importantly, by postsynaptic inhibition of 2-AG synthesis in burst-firing neurons ( Figures 6E and 6F) . The regulatory function of presynaptic b-neurexins in release is likely physiologically important since the b-neurexin KO in the CA1 region severely impaired contextual fear conditioning (Figure 7) .
To the best of our knowledge, our findings represent the first description of trans-synaptic control of endocannabinoid signaling by neurexins, complementing previous observations of a role of postsynaptic neuroligin-3 in regulating the endocannabinoid tone (Fö ldy et al., 2013) . Tonic endocannabinoid signaling at excitatory synapses has not previously been documented, but anatomical evidence supports the presence of DGL-a (which synthesizes the endocannabinoid 2-AG; Figure 4A ) and of CB1Rs at excitatory spine synapses in the hippocampus (Katona et al., 2006; Kawamura et al., 2006) . Moreover, several studies showed that the CB1R-agonist WIN inhibits extracellular stimulation-evoked glutamate release onto CA1 pyramidal neurons (Hajos et al., 2001; Ohno-Shosaku et al., 2002; Kawamura et al., 2006; Takahashi and Castillo, 2006) . Excitatory synapses onto CA1 pyramidal neurons exhibit evidence of phasic, but not tonic, endocannabinoid signaling (Ohno-Shosaku et al., 2002; Fö ldy et al., 2013) , suggesting that the regulation of tonic 2-AG signaling by b-neurexins is synapse-specific and further emphasizing how the identity of trans-synaptic neurexin complexes can dictate function. No previous evidence has linked endocannabinoid signaling to modulation of presynaptic LTP of excitatory synapses, although CB1R activation has been implicated in LTD (Peterfi et al., 2012; Han et al., 2012) .
Mechanistically, the large effects of the b-neurexin KO in the presence of the more abundant a-neurexins ( Figures 1A and  S1 ) suggest that b-neurexins perform unique non-redundant functions. The presynaptic action of b-neurexins ( Figures 5  and 6 ), the SS4-dependence of the rescue ( Figure 3E ), and the rescue of the presynaptic b-neurexin KO phenotype by blocking postsynaptic synthesis of 2-AG (Figures 4 and 6 ) demonstrate that the functions of b-neurexins involve trans-synaptic ligand interactions. It is intriguing that some splice variants of neuroligin-1 only bind to b-neurexins, but not to a-neurexins ( Figure S5I ), and that deletion of neuroligin-3 abolishes tonic endocannabinoid signaling at inhibitory synapses of CCK basket cells (Fö ldy et al., 2013) . Although the b-neurexin KO led to the opposite effect at excitatory synapses on subiculum burst-firing neurons, namely, an enhancement of basal endocannabinoid signaling, it is possible that they are due to the same principal process: trans-synaptic regulation of endocannabinoid signaling that involves interactions of specific neurexin splice-variants with particular neuroligin isoforms. Alternatively, it is possible that as yet unknown b-neurexin-specific ligands mediate their functions, or that a-and b-neurexins are localized to distinct synaptic sites in a neuron.
The b-neurexin KO phenotype resembles that of neurexin-3 SS4 knockin mice in that both genetic manipulations reveal a requirement for neurexins lacking an insert in SS4 ( Figure 3E ; Aoto et al., 2013) . However, the phenotypes of these mutations are very different. While the b-neurexin KO caused a decrease in presynaptic release probability and a loss of presynaptic LTP without changes in postsynaptic parameters, the opposite was observed in SS4 knockin mice expressing neurexin-3 with constitutively spliced-in SS4 (Aoto et al., 2013) . This difference in phenotypes is likely due to the fact that the SS4 knockin affects all a-and b-transcripts of ONE particular neurexin gene, whereas the b-neurexin triple KO affects all b-transcripts, but not a-transcripts, of all neurexin genes (which primarily express a-neurexins). Thus, the only overlap between the two genetic manipulations involves relatively small amounts of neurexin-3b mRNAs. Any phenotypic overlap of these manipulations likely would have been occluded by their more dramatic general phenotypes, although the small decrease in mEPSC amplitude and AMPAR surface levels in b-neurexin KO synapses (Figures 3A and S4F) may be due to the mechanism described by Aoto et al. (2013) for the neurexin-3 SS4 knockin.
Independent of the molecular mechanism underlying the selective functional role of b-neurexins in regulating excitatory synaptic strength, this role likely has significant implications for neural circuit dynamics (Figures 7A-7D) . Information processing by neural circuits involves continuous modulation of synaptic strength at specific sites, such that the input/output relations of a circuit depend on how action potentials are transformed into synaptic signals that eventually cause firing-or inhibition of firing-of the circuit output neurons. Endocannabinoids have emerged as major regulators of circuit dynamics (Katona and Freund, 2008; Castillo et al., 2012; Melis et al., 2014) . Thus, the control of endocannabinoid signaling by trans-synaptically acting b-neurexins, which in turn are regulated by alternative splicing, likely impacts circuit dynamics in many brain regions. Understanding such dynamics will be essential for understanding behavior in general, and the conditional b-neurexin KO mice provide a useful tool for region-specific modulation of circuit dynamics in order to probe its behavioral relevance.
EXPERIMENTAL PROCEDURES
In all experiments, the researcher was blinded to the genetic manipulation. All plasmids are available upon request, and the mice described here were deposited in Jackson Labs for distribution. Brief experimental procedures are listed here. For details, please see the Supplemental Experimental Procedures.
Mouse Generation and Husbandry
Neurexin-b-floxed (NBF) mice were generated by homologous recombination targeting the 5 0 unique exon for each of the three b-neurexin genes that is not shared with its a-neurexin counterparts. All procedures conformed to NIH Guidelines for the Care and Use of Laboratory Animals and were approved by the Stanford University Administrative Panel on Laboratory Animal Care.
mRNA Measurements mRNA measurements were performed using qRT-PCR on RNA isolated from $P30 mouse brain tissues using the RNAqueous-Micro RNA Isolation Kit (Invitrogen). Reactions for a-and b-neurexins and GAPDH (internal control) were run with primers and probes as described in the Supplemental Experimental Procedures.
Neuron Cultures
Cortical neurons were cultured from newborn NBF mice, infected on DIV 3-4 with lentiviruses, transfected using the calcium phosphate method when indicated, and analyzed at DIV 14-16.
Virus Preparations
Nuclear localized EGFP-Cre and EGFP-DCre fusion proteins deliverable by lentiviruses were from previously described vectors (Kaeser et al., 2011) . All neurexin-1b rescue constructs were previously described mouse cDNAs expressed from separate lentiviruses (Aoto et al., 2013) . For in vivo infections, we employed an AAV-DJ strain that is highly efficient in vivo as previously described .
Stereotactic Injections
Stereotactic injections of AAVs were performed as previously described . Efficiency and localization of AAV expression were confirmed by fluorescence of nuclear EGFP encoded by the expressed inactive and active EGFP-Cre-recombinase fusion proteins.
Ca
2+ Imaging
A chimeric GCaMP5G-Syb2 was made and used in order to target GCaMP5G calcium sensor to presynaptic terminals as described in the Supplemental . Open-field behavior (analyzed in three 5-min segments) was quantified as spatial confinement (C, left), low-mobility bouts (C, center), and total distance traveled (C, right). Fear conditioning training exposed mice to three 30-s tones ending with 2-s electrical foot shocks separated by 1-min intervals (D; left, graphs, cumulative distributions; right, summary graphs, mean fear conditioning memory as measured by freezing). Data are means ± SEM; the numbers of mice examined are shown in the graphs. Statistical analysis was performed by Student's t test (*p < 0.05).
(legend continued on next page) Experimental Procedures. Neuronal morphology was visualized by sparse Ca 2+ -phosphate transfection with mCherry expression construct, and imaging was performed on a Zeiss LSM 510 confocal microscope.
Electrophysiology
For details of electrophysiological recordings from cultured neurons and acute slices, see the Supplemental Experimental Procedures.
Fear Conditioning
Fear conditioning and open-field behavioral analysis was essentially performed as previously described .
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures and seven figures and can be found with this article online at http://dx.doi. org/10.1016/j.cell.2015.06.056.
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